Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes

Patricia K Coyle, Bruce A Cohen, Thomas Leist, Clyde Markowitz, MerriKay Oleen-Burkey, Marc Schwartz, Mark J Tullman, Howard Zwibel, Patricia K Coyle, Bruce A Cohen, Thomas Leist, Clyde Markowitz, MerriKay Oleen-Burkey, Marc Schwartz, Mark J Tullman, Howard Zwibel

Abstract

Background: Data sources for MS research are numerous but rarely provide an objective measure of drug therapy compliance coupled with patient-reported health outcomes. The objective of this paper is to describe the methods and baseline characteristics of the Therapy Optimization in MS (TOP MS) study designed to investigate the relationship between disease-modifying therapy compliance and health outcomes.

Methods: TOP MS was designed as a prospective, observational, nationwide patient-focused study using an internet portal for data entry. The protocol was reviewed and approved by Sterling IRB. The study was registered with ClinicalTrials.gov. It captured structured survey data monthly from MS patients recruited by specialty pharmacies. Data collection included the clinical characteristics of MS such as MS relapses. Disability, quality of life and work productivity and activity impairment were assessed quarterly with well-validated scales. When events like severe fatigue or new or worsening depression were reported, feedback was provided to treating physicians. The therapy compliance measure was derived from pharmacy drug shipment records uploaded to the study database. The data presented in this paper use descriptive statistics.

Results: The TOP MS Study enrolled 2966 participants receiving their disease-modifying therapy (DMT) from specialty pharmacies. The mean age of the sample was 49 years, 80.4% were female, 89.9% were Caucasian and 55.7% were employed full or part time. Mean time since first symptoms was 11.5 years; mean duration since diagnosis was 9.5 years. Patient-reported EDSS was 3.5; 72.2% had a relapsing-remitting disease course. The most commonly reported symptoms at the time of enrollment were fatigue (74.7%), impaired coordination or balance (61.8%) and numbness and tingling (61.2%). Half of the sample was using glatiramer acetate and half was using beta-interferons.

Conclusion: Demographic and clinical characteristics of the TOP MS sample at enrollment are consistent with other community-based MS samples, and the sample appears to be representative of DMT users in the US. TOP MS data can be used to explore the associations between disease-modifying therapy compliance and health outcomes.

Trial registration: ClinicalTrials.gov (NCT00819000).

References

    1. Multiple sclerosis international federation. About MS –what is MS? 2013. [ ]
    1. Stüve O, Oksenberg J. In: GeneReviews™.[Internet] Pagon RA, Adam MP, Bird TD, editor. Seattle (WA): University of Washington; 2006. Multiple sclerosis overview; pp. 1993–2013. ([Updated 2010 May 11]). [ ]
    1. National MS society (NMSS) – about MS -- what we know about MS --treatments 2013. [ ]
    1. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44–47. doi: 10.1111/j.1524-4733.2007.00213.x.
    1. Salter AR, Tyry T, Vollmer T, Cutter GR, Marrie RA. Seeing in NARCOMS: a look at vision-related quality of life in the NARCOMS registry. Mult Scler J. 2013;19:953–960. doi: 10.1177/1352458512469694.
    1. Jacobs LD, Wende KE, Brownscheidle CM, Apatoff B, Coyle PK, Goodman A, Gottesman MH, Granger CV, Greenberg SJ, Herbert J, Krupp L, Lava NS, Hihai C, Miller AE, Perel A, Smith CR, Snyder D. and The New York State Multiple Sclerosis Consortium. A profile of multiple sclerosis: the New York state multiple sclerosis consortium. Mult Scler. 1999;5:369–376.
    1. Oleen-Burkey MA, Dor A, Castelli-Haley J, Lage MJ. The relationship between alternative medication possession ratio thresholds and outcomes: evidence from the use of glatiramer acetate. J Med Econ. 2011;14:739–747. doi: 10.3111/13696998.2011.618517.
    1. Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA. Impact of adherence to interferons in the treatment of multiple sclerosis. Clin Drug Invest. 2010;30:89–100. doi: 10.2165/11533330-000000000-00000.
    1. Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical claim validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ. 2010;13:618–625. doi: 10.3111/13696998.2010.523670.
    1. Bluml BM. Definition of medication therapy management: development of professionwide consensus. J Am Pharm Assoc (2003) 2005;45:566–572. doi: 10.1331/1544345055001274.
    1. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records. Methods, validity, and applications. J Clin Epidemiol. 1997;50:105–116. doi: 10.1016/S0895-4356(96)00268-5.
    1. Elston Lafata J, Cerghet M, Dobie L, Schultz L, Tunceli K, Reuther J, Elias S. Adherence and persistence to disease modifying agents among patients with relapsing-remitting multiple sclerosis. J Am Pharm Assoc. 2008;48:752–757. doi: 10.1331/JAPhA.2008.07116.
    1. Coulthard-Morris L. In: Multiple Sclerosis: Diagnosis, Medical Management, and Rehabilitation. Burks JS, Johnson KP, editor. New York: Demos Medical Publishing; 2000. Clinical and rehabilitation outcome measures.
    1. Ware JE, Jr, Kosinski M, Turner-Bowker DM, Gandek B. How to Score Version 2 of the SF-12® Health Survey (With a Supplement Documenting Version 1) Lincoln: QualityMetric Incorporated; 2002.
    1. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353–365. doi: 10.2165/00019053-199304050-00006.
    1. Krupp LB, LaRocca NG, Muir-Nash, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46:1121–1123. doi: 10.1001/archneur.1989.00520460115022.
    1. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–613. doi: 10.1046/j.1525-1497.2001.016009606.x.
    1. Kroenke K, Spitzer RL, Williams JBW. The patient health questionnaire-2: validity of a Two-item depression screener. Med Care. 2003;41:1284–1292. doi: 10.1097/01.MLR.0000093487.78664.3C.
    1. Sullivan JJL, Edgley K, Dehoux E. A survey of multiple sclerosis. Part 1:Perceived cognitive problems and compensatory strategy use. Can J Rehabil. 1990;4:99–105.
    1. Garber MC, Nau DP, Erickson SR, Aikens JE, Lawrence JB. The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care. 2004;42:649–652. doi: 10.1097/01.mlr.0000129496.05898.02.
    1. Inui TS, Carter WB, Pecoraro RF. Screening for noncompliance among patients with hypertension: is self-report the best available? Med Care. 1981;19:1061–1064. doi: 10.1097/00005650-198110000-00008.
    1. Bruce JM, Hancock LM, Lynch SG. Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report. Mult Scler. 2010;16:112–120. doi: 10.1177/1352458509351897.
    1. Ingram G, Colley E, Ben-Shlomo Y, Cossburn M, Hirst CL, Pickersgill TP, Robertson NP. Validity of patient-derived disability and clinical data in multiple sclerosis. Mult Scler. 2010;16:472–479. doi: 10.1177/1352458509358902.
    1. Bliven BD, Kaufman SE, Spertus JA. Electronic collection of health-related quality of life data: validity, time benefits and patient preference. Qual Life Res. 2001;10:15–22. doi: 10.1023/A:1016740312904.
    1. Lewis G, Sharp D, Bartholomew J, Pelosi AJ. Computerized assessment of common mental disorders in primary care: effect on clinical outcome. Fam Pract. 1996;13:120–126. doi: 10.1093/fampra/13.2.120.
    1. Minden SL, Frankel D, Hadden L, Perloff J, Srinath KP, Hoaglin DC. The Sonya Slifka longitudinal multiple sclerosis study: methods and sample characteristics. Mult Scler. 2006;12:24–38. doi: 10.1191/135248506ms1262oa.
    1. Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, Suchet L, Hyde R, Balla I, Frohman EM, Kieseiier BC. for the GAP Study Group. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2010;18:69–77.
    1. Marrie RA. Observational studies of treatment effectiveness: useful, useless or somewhere in between? (Editorial) Mult Scler J. 2013;19:707–708. doi: 10.1177/1352458512465136.
    1. Jongen PJ, Sanders E, Zwanikken C, Koeman J, Visser LH, Koopmans P, Lehnick D. Adherence to monthly online self-assessments for short-term monitoring: a 1-year study in relapsing-remitting multiple sclerosis patients after start of disease modifying treatment. Patient Prefer Adherence. 2013;7:293–300.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner